Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Why Recursion Pharmaceuticals Stock Is Sinking Today
Shares of Recursion Pharmaceuticals (RXRX -5.54%) were sinking 8.2% lower as of 10:57 a.m. ET on Monday.
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years, so naturally, investors want to cash in by investing in those companies best positioned to profit from AI.
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (RXRX -5.17%).
This Biotech Stock Could Be the Best Investment of the Decade
It's typically not too difficult to find a company that should perform well for the next couple of years. Two years isn't very long, after all, and the stock market's dynamics tend to dictate performance more.
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development.
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals Inc RXRX is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham.
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Lina Nilsson - Senior Vice President & Head of Platform Ben Taylor - Chief Financial Officer Conference Call Participants Chris Gibson Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead.
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago.
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
Why Recursion Pharmaceuticals Stock Is Soaring Today
Shares of Recursion Pharmaceuticals (RXRX 16.12%) had soared by 15.8% as of 12:06 p.m. ET on Friday.
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
